(S1 (S (S (NP (NP (JJ Isotype-specific) (NNS inhibitors)) (PP (IN of) (NP (NP (DT the) (JJ glycolytic) (JJ key) (NN regulator)) (NN pyruvate) (NN kinase) (NN subtype) (NN M2)))) (ADVP (RB moderately)) (VP (VBP decelerate) (NP (NN tumor) (NN cell) (NN proliferation)))) (. .)))
(S1 (S (S (NP (NN Tumor) (NNS cells)) (VP (VBP express) (NP (NP (NP (DT the) (JJ glycolytic) (NN regulator) (NN pyruvate) (NN kinase) (NN subtype) (NN M2)) (PRN (-LRB- -LRB-) (NP (NN M2-PK)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB occur) (PP (IN in) (NP (NP (NP (DT a) (JJ tetrameric) (NN form)) (PP (IN with) (NP (NP (JJ high) (NN affinity)) (PP (TO to) (NP (NP (PRP$ its) (NN substrate) (NN phosphoenolpyruvate)) (PRN (-LRB- -LRB-) (NP (NN PEP)) (-RRB- -RRB-))))))) (CC and) (NP (NP (DT a) (JJ dimeric) (NN form)) (PP (IN with) (NP (DT a) (JJ low) (NN PEP) (NN affinity))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN transition)) (PP (IN between) (NP (DT both) (NNS conformations)))) (VP (VP (VBZ contributes) (PP (TO to) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (NN glycolysis)))))) (CC and) (VP (VBZ is) (ADJP (JJ important) (PP (IN for) (NP (NN tumor) (NN cell) (NP (NP (NN proliferation)) (CC and) (NP (NN survival))))))))) (. .)))
(S1 (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBN targeted) (NP (NN M2-PK)) (PP (IN by) (NP (NP (JJ synthetic) (NN peptide) (NNS aptamers)) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB specifically)) (VP (VP (VBP bind) (PP (TO to) (NP (NN M2-PK)))) (CC and) (VP (VB shift) (NP (NP (DT the) (NN isoenzyme)) (PP (IN into) (NP (NP (PRP$ its) (JJ low) (NN affinity)) (JJ dimeric) (NN conformation)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NP (JJ aptamer-induced) (NN dimerization)) (CC and) (NP (NN inactivation))) (PP (IN of) (NP (NN M2-PK)))) (VP (VBD led) (PP (TO to) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN PK) (JJ mass-action) (NN ratio)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NN ATP:ADP) (NN ratio)) (PP (IN in) (NP (DT the) (NN target) (NNS cells)))))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ M2-PK-binding) (NN peptide) (NNS aptamers)))) (ADVP (RB moderately)) (VP (VBD reduced) (NP (NP (DT the) (NN growth)) (PP (IN of) (NP (VBN immortalized) (NN NIH3T3) (NN cell) (NNS populations)))) (PP (PP (IN by) (NP (NN decelerating) (NN cell) (NN proliferation))) (, ,) (CC but) (PP (IN without) (S (VP (VBG affecting) (NP (JJ apoptotic) (NN cell) (NN death)))))))) (. .)))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (DT the) (JJ M2-PK-binding) (NN peptide) (NNS aptamers)) (ADVP (RB also)) (VP (VBD reduced) (NP (NP (DT the) (NN proliferation) (NN rate)) (PP (IN of) (NP (JJ human) (NN U-2) (NN OS) (NN osteosarcoma) (NNS cells)))))) (. .)))
(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (VP (VBD developed) (NP (NP (DT the) (JJ first) (JJ specific) (NNS inhibitors)) (PP (IN of) (NP (DT the) (NN pyruvate) (NN kinase) (NN isoenzyme) (NN type) (NN M2))))) (CC and) (VP (VBP present) (NP (NN evidence) (SBAR (IN that) (S (NP (DT these) (NNS inhibitors)) (ADVP (RB moderately)) (VP (VBP decelerate) (NP (NN tumor) (NN cell) (NN proliferation)))))))) (. .)))
